Descovy
Drug
Gilead Sciences Inc
Total Payments
$81.5M
Transactions
20,229
Doctors
6,177
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $3.8M | 2,882 | 1,134 |
| 2023 | $2.5M | 2,958 | 1,177 |
| 2022 | $1.3M | 2,079 | 1,126 |
| 2021 | $2.5M | 2,824 | 1,799 |
| 2020 | $17.8M | 2,910 | 1,283 |
| 2019 | $24.5M | 4,010 | 1,098 |
| 2018 | $26.8M | 1,452 | 18 |
| 2017 | $2.4M | 1,114 | 283 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $75.1M | 4,143 | 92.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4.3M | 2,177 | 5.2% |
| Travel and Lodging | $886,785 | 2,583 | 1.1% |
| Food and Beverage | $722,173 | 10,901 | 0.9% |
| Consulting Fee | $561,256 | 220 | 0.7% |
| Space rental or facility fees (teaching hospital only) | $13,000 | 2 | 0.0% |
| Education | $1,892 | 203 | 0.0% |
Payments by Type
Research
$75.1M
4,143 transactions
General
$6.4M
16,086 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are At Risk of HIV-1 Infection | Gilead Sciences, Inc. | $65.3M | 1 |
| Analysis through REPRIEVE A5332/A5333s of the effect of cart regimen on major adverse cardiovascular events, atherosclerotic plaque, and major non-cardiovascular events | Gilead Sciences, Inc. | $1.5M | 0 |
| A Phase 3b, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects who are Virologically Suppressed on Regimens containing ABC/3TC | Gilead Sciences Inc | $1.1M | 1 |
| A Phase 3b, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects who are Virologically Suppressed on Regimens containing ABC/3TC | Gilead Sciences, Inc. | $1.1M | 1 |
| In vitro and in vivo studies of the relative mitochondrial toxicity of tenofovir alafenamide (TAF) vs. tenofovir disoproxil fumarate (TDF) | Gilead Sciences, Inc. | $461,933 | 0 |
| Analysis through REPRIEVE A5332/a5333s of the effect of cart regimen on major adverse cardiovascular events, atherosclerotic plaque, and major non-cardiovascular events | Gilead Sciences Inc | $432,981 | 0 |
| Expanding HIV Prevention Options for Adolescent Girls and young Women (Project ENGAGE) | Gilead Sciences, Inc. | $370,510 | 0 |
| Community-based, peer-delivered PrEP for female sex workers in rural Uganda | Gilead Sciences, Inc. | $342,000 | 0 |
| Making PrEP Smart: An HIV testing and PrEP electronic support tool for women on PrEP | Gilead Sciences, Inc. | $331,724 | 0 |
| Mobile delivery of PrEP at a Syringe Services Program: A Pilot Study | Gilead Sciences, Inc. | $330,321 | 0 |
| Assessing quality of life and differential adherence among people living with HIV and comorbidities | Gilead Sciences, Inc. | $296,718 | 0 |
| PrEP-related Attitudes, Intentions, and Behaviors Among Adolescent and Young Adult Transgender Men | Gilead Sciences, Inc. | $286,000 | 0 |
| Re-engagement, Re-initiation and Retention in PrEP Care in Transgender Women: Designing a Gender-Affirming R-cubed Intervention | Gilead Sciences, Inc. | $278,713 | 0 |
| Switch TVD+3rd Agent - F/TAF+3rd Agent, 6 month enrollment (global): A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV 1 Positive Subjects who are Virologically Suppressed on Regimens containing FTC/TDF | Gilead Sciences Inc | $268,337 | 1 |
| Impact of Switching to a TAF-based Regimen in a Real-World Cohort of Older HIV-Infected Patients | Gilead Sciences, Inc. | $261,835 | 0 |
| A Phase 2/3, Open Label, Multi-Cohort Switch Study to Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV 1 Infected Children and Adolescents Virologically Suppressed on a 2 NRTI Containing Regimen | Gilead Sciences, Inc. | $236,392 | 0 |
| Identifying novel implementation strategies to increase PrEP uptake among South African men: a discrete choice experiment on delivery preferences | Gilead Sciences, Inc. | $227,850 | 0 |
| Exploring Needs, Barriers, and Opportunities for Integration of HIV Pre-Exposure Prophylaxis (PrEP) Prescription in Psychiatry: A Mixed Methods Study of Patients and Psychiatrists | Gilead Sciences, Inc. | $209,860 | 0 |
| Implementation Evaluation of Home Follow-up After Mobile Clinic PrEP Initiation for a Predominantly Immigrant Latino MSM Population in Miami | Gilead Sciences, Inc. | $204,424 | 0 |
| F/TAF Switch Study for Transgender Individuals for HIV Pre-exposure Prophylaxis (TAF4TRANS) | Gilead Sciences, Inc. | $190,574 | 0 |
Top Doctors Receiving Payments for Descovy
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| David Parker | — | Punta Gorda, FL | $73.9M | 4,100 |
| , M.D | Internal Medicine | Seattle, WA | $1.3M | 135 |
| , M.D | Family Medicine | Johnston, RI | $199,867 | 241 |
| , D.O | Geriatric Medicine | Phoenix, AZ | $141,743 | 185 |
| , D.O | Family Medicine | Oakland Park, FL | $137,253 | 131 |
| , MD | Internal Medicine | Washington, DC | $133,478 | 143 |
| , MD | Internal Medicine | Stony Brook, NY | $130,766 | 129 |
| , MD | Adult Medicine | Washington, DC | $130,226 | 35 |
| , D.O | Family Medicine | Berkley, MI | $126,024 | 149 |
| , MD | Internal Medicine | Fort Lauderdale, FL | $117,960 | 153 |
| , DO | Family Medicine | Columbus, OH | $100,272 | 98 |
| , M.D | Infectious Disease | San Antonio, TX | $90,510 | 158 |
| , M.D | Gastroenterology | Los Angeles, CA | $85,496 | 80 |
| , M.D | Family Medicine | Austin, TX | $80,292 | 75 |
| , MD | Adult Medicine | Phoenix, AZ | $77,976 | 97 |
| , MD, PHD | Infectious Disease | Seattle, WA | $77,604 | 119 |
| , MD | Infectious Disease | Jersey City, NJ | $76,645 | 80 |
| , M.D | Infectious Disease | Los Angeles, CA | $71,781 | 58 |
| , M.D | Family Medicine | Seattle, WA | $70,500 | 96 |
| , M.D | Infectious Disease | Newburyport, MA | $69,293 | 72 |
| , MD | Internal Medicine | New York, NY | $68,953 | 101 |
| , M.D | Family Medicine | Indianapolis, IN | $65,439 | 74 |
| , MD | Infectious Disease | New Haven, CT | $61,491 | 63 |
| , MD | Internal Medicine | San Francisco, CA | $58,865 | 70 |
| , M.D | Infectious Disease | Southport, CT | $57,827 | 57 |
Ad
Manufacturing Companies
- Gilead Sciences, Inc. $79.2M
- Gilead Sciences Inc $2.4M
Product Information
- Type Drug
- Total Payments $81.5M
- Total Doctors 6,177
- Transactions 20,229
About Descovy
Descovy is a drug associated with $81.5M in payments to 6,177 healthcare providers, recorded across 20,229 transactions in the CMS Open Payments database. The primary manufacturer is Gilead Sciences Inc.
Payment data is available from 2017 to 2024. In 2024, $3.8M was paid across 2,882 transactions to 1,134 doctors.
The most common payment nature for Descovy is "Unspecified" ($75.1M, 92.1% of total).
Descovy is associated with 20 research studies, including "A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are At Risk of HIV-1 Infection" ($65.3M).